Vosoritide Phase 3 Hypochondroplasia Trial Published in NEJM Evidence

A new publication titled "A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia" was released on September 9, 2026. The paper appears in NEJM Evidence, a journal published by the New England Journal of Medicine group. Vosoritide is an approved therapy, and this publication describes a Phase 3 trial conducted in children with hypochondroplasia. The listed event data identifies this as a publication record, indicating the trial results have been made available in the medical literature. No specific findings, outcomes, or efficacy data beyond the title and journal placement are included in the available event information. Readers interested in the details of the trial design, patient population, or results should consult the original publication directly. This brief reports only the fact that the publication exists and where it was released, without characterizing its content further. For general background on vosoritide, including its approved uses and mechanism, readers can consult the compound overview.